Newcells Biotech is collaborating with industry leaders and expert academics in a European-wide interdisciplinary initiative to develop animal-free methods for drug safety evaluations. The initiative (the EU funded in3 project) is driven
There are few topics more controversial than the use of animals in science, despite the enormous contribution animal experimentation continues to make to the development of new medicines and surgical techniques. Animals
Newcastle-based human stem cell model specialists, Newcells Biotech, have secured a total of £5.25m worth of funding to accelerate their growth plans in the international life sciences market. The funding comes from
The kidney proximal tubule is of key interest in drug discovery. This is due to its primary role in the excretion and reabsorption of xenobiotics, such as drugs and carcinogens. Current primary
In line with our previous Covid-19 Action Plan, Newcells Biotech has continued to review and invest in measures to reduce the risk to its staff and our wider community from the Covid-19
The proximal tubule is key due to its role in the excretion and reabsorption of many xenobiotic compounds. Due to the high costs associated with drug discovery and the clinical demand for
Covid-19 is known to infect the lungs. However, the dynamics of viral infection and replication are poorly understood. Alongside the Liverpool School of Tropical Medicine, we have been working to develop a
At Newcells Biotech, we specialise in the large-scale production of retinal organoids for the purpose of in vitro toxicology efficacy studies and disease modelling. Our differentiation protocols generate organoids which are fully stratified with the presence of
Newcells Biotech, experts in induced pluripotent stem cell (iPSC) differentiation and assay construction, have confirmed their human lung epithelium model as an effective platform for modelling SARS-CoV-2 infection and replication. Their work alongside the Liverpool School of Tropical Medicine (LTSM) Centre for Drugs and Diagnostics will be crucial in helping
Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster. The purpose-built space in the city centre site
Vaccination can be regarded as one of biomedicines biggest triumphs. Since Edward Jenner pioneered the smallpox vaccine in 1798, subsequent morbidity and mortality rates have declined for a multitude of diseases, such as Diphtheria, Whooping Cough and Measles.1 However, despite the success of these global vaccination
Biologics represent a new modality of drug molecules which is rapidly expanding in market share and in the number of biologics gaining regulatory approval each year. Biologics are defined as a diverse
